Who Supplies Metformin to India from SWITZERLAND

To import finished pharmaceutical formulations containing Metformin into India, the foreign manufacturer must obtain an Import Registration Certificate and an Import License from the Central Drugs Standard Control Organization (CDSCO). The application requires submission of Form 40 or 41, along with a No Objection Certificate (NOC) from the manufacturer. The registration process includes providing a Certificate of Pharmaceutical Product (CoPP), Good Manufacturing Practice (GMP) certificate, and stability data. The timeline for import drug registration varies but typically ranges from 6 to 12 months. For Metformin formulations under HS Code 30049099, compliance with Indian Pharmacopoeia standards and submission of a Certificate of Analysis (CoA) for each batch are mandatory. Additionally, the manufacturer must ensure that the product meets the quality, safety, and efficacy requirements as stipulated by the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945.

Imported Metformin formulations must undergo quality testing at CDSCO-approved laboratories in India. Each batch requires a Certificate of Analysis (CoA) confirming compliance with Indian Pharmacopoeia standards. Stability data, particularly for ICH Zone IV conditions, must be provided to demonstrate the product's shelf-life under Indian climatic conditions. Port inspection by customs drug inspectors is conducted to verify the authenticity and quality of the imported products. If a batch fails quality testing, it may be rejected, leading to re-exportation or destruction, depending on the circumstances. Common quality issues include deviations in dissolution profiles, impurity levels, and packaging defects.

Between 2024 and 2026, the CDSCO has implemented stricter regulations for the import of pharmaceutical products, including mandatory import registration and licenses for all imported drugs. The introduction of the Production Linked Incentive (PLI) scheme has incentivized domestic manufacturing, potentially affecting the volume of finished formulation imports. Bilateral agreements between India and Switzerland have facilitated smoother trade relations, with mutual recognition of Good Manufacturing Practices (GMP) and streamlined import procedures.

India imports finished Metformin formulations to meet the demand for patented and branded products, as well as specific dosage forms not produced domestically. The domestic capacity for Metformin production is substantial; however, imports supplement the market by providing specialized formulations and ensuring a consistent supply. The Indian Metformin market is valued at approximately $466.4 million, with 528 exporters supplying to 160 countries. The import of finished formulations allows for quicker market entry and access to advanced formulations, benefiting both healthcare providers and patients.

The Basic Customs Duty (BCD) for Metformin formulations under HS Code 30049099 is 10%. An additional Social Welfare Surcharge (SWS) of 10% is applied, resulting in a total duty of 20%. The Goods and Services Tax (GST) at 12% is levied on the imported value. There are no exemptions or concessional rates for imports from Switzerland. The total landed duty percentage is approximately 32.4%, comprising BCD, SWS, and GST.

Switzerland is a preferred source for Metformin formulations due to its high-quality manufacturing standards, adherence to international GMP, and the availability of patented or specialized formulations not produced in India. Swiss manufacturers offer formulations with unique delivery systems, extended-release profiles, and combination therapies that cater to specific patient needs. While other countries like China, Germany, and the United States also supply Metformin formulations, Switzerland's reputation for quality and innovation provides a competitive advantage in the Indian market.

India imports Metformin formulations from Switzerland to access high-quality products, including patented formulations and specialized dosage forms not available domestically. Swiss manufacturers offer advanced delivery systems and combination therapies that cater to specific patient needs, enhancing treatment outcomes. The reputation of Swiss pharmaceutical companies for quality and innovation makes them a preferred choice for Indian importers seeking reliable and effective Metformin formulations.

Compared to other sources like China, the European Union, and the United States, Switzerland offers a competitive advantage in terms of product quality, regulatory compliance, and innovation. Swiss manufacturers adhere to stringent GMP standards and provide formulations with unique delivery systems and extended-release profiles. While other countries may offer lower-priced products, the superior quality and reliability of Swiss formulations justify the higher cost for Indian importers.

Potential risks for Indian importers include single-source dependency, currency fluctuations, regulatory changes, quality incidents, and shipping disruptions. To mitigate these risks, importers should diversify their supplier base, maintain adequate inventory levels, and establish contingency plans for supply chain disruptions. Regular communication with suppliers and staying informed about regulatory changes are essential for proactive risk management.

1. 1Dual-Sourcing: Engage multiple suppliers to reduce dependency on a single source and mitigate supply chain risks.
2. 2Inventory Planning: Maintain optimal inventory levels to buffer against potential supply disruptions.
3. 3Payment Terms: Negotiate favorable payment terms, such as Letters of Credit (LC), Documents Against Acceptance (DA), or Documents Against Payment (DP), to manage cash flow effectively.
4. 4Supplier Qualification: Conduct thorough due diligence on potential suppliers, including audits of manufacturing facilities and review of quality certifications.
5. 5Regulatory Compliance: Stay updated on Indian import regulations and ensure all necessary licenses and certifications are in place to avoid delays and penalties.

1. 1DGFT Importer Exporter Code (IEC): Obtain an IEC from the Directorate General of Foreign Trade.
2. 2CDSCO Registration: Apply for registration with CDSCO, including submission of Form 40 or 41.
3. 3Import License: Secure an import license from CDSCO for each product.
4. 4No Objection Certificate (NOC):